Jennison Associates’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-61,787
| Closed | -$17.2M | – | 570 |
|
|
2023
Q1 | $17.2M | Buy |
+61,787
| New | +$17.1M | 0.02% | 341 |
|
|
2021
Q2 | – | Sell |
-65,838
| Closed | -$18.4M | – | 675 |
|
|
2021
Q1 | $18.4M | Buy |
65,838
+32,082
| +95% | +$8.65M | 0.01% | 365 |
|
|
2020
Q4 | $8.27M | Buy |
+33,756
| New | +$8.71M | 0.01% | 423 |
|
|
2020
Q2 | – | Sell |
-91,368
| Closed | -$28.9M | – | 633 |
|
|
2020
Q1 | $28.9M | Buy |
91,368
+89,297
| +4,312% | +$27.1M | 0.04% | 208 |
|
|
2019
Q4 | $615K | Buy |
+2,071
| New | +$575K | ﹤0.01% | 581 |
|
|
2019
Q3 | – | Sell |
-3,232
| Closed | -$756K | – | 644 |
|
|
2019
Q2 | $756K | Sell |
3,232
-100
| -3% | -$23.1K | ﹤0.01% | 589 |
|
|
2019
Q1 | $788K | Buy |
+3,332
| New | +$1.05M | ﹤0.01% | 575 |
|
|
2018
Q2 | – | Sell |
-230,771
| Closed | -$63.2M | – | 659 |
|
|
2018
Q1 | $63.2M | Buy |
230,771
+105,530
| +84% | +$32.8M | 0.06% | 223 |
|
|
2017
Q4 | $39.9M | Buy |
125,241
+27,827
| +29% | +$8.93M | 0.04% | 292 |
|
|
2017
Q3 | $30.5M | Sell |
97,414
-26,284
| -21% | -$7.78M | 0.03% | 342 |
|
|
2017
Q2 | $33.6M | Sell |
123,698
-10,215
| -8% | -$2.7M | 0.04% | 323 |
|
|
2017
Q1 | $36.6M | Sell |
133,913
-8,373
| -6% | -$2.37M | 0.04% | 325 |
|
|
2016
Q4 | $40.3M | Sell |
142,286
-2,472,097
| -95% | -$733M | 0.05% | 298 |
|
|
2016
Q3 | $818M | Buy |
2,614,383
+609,120
| +30% | +$180M | 0.88% | 38 |
|
|
2016
Q2 | $485M | Sell |
2,005,263
-1,460,011
| -42% | -$385M | 0.53% | 48 |
|
|
2016
Q1 | $902M | Buy |
3,465,274
+82,049
| +2% | +$21.7M | 0.95% | 30 |
|
|
2015
Q4 | $1.04B | Sell |
3,383,225
-678,458
| -17% | -$195M | 1.02% | 29 |
|
|
2015
Q3 | $1.19B | Sell |
4,061,683
-786,414
| -16% | -$260M | 1.21% | 18 |
|
|
2015
Q2 | $1.96B | Sell |
4,848,097
-247,504
| -5% | -$99.3M | 1.8% | 7 |
|
|
2015
Q1 | $2.15B | Sell |
5,095,601
-524,062
| -9% | -$207M | 1.97% | 5 |
|
|
2014
Q4 | $1.91B | Sell |
5,619,663
-188,022
| -3% | -$60.8M | 1.78% | 5 |
|
|
2014
Q3 | $1.92B | Sell |
5,807,685
-473,199
| -8% | -$156M | 1.78% | 5 |
|
|
2014
Q2 | $1.98B | Sell |
6,280,884
-56,269
| -0.9% | -$16.9M | 1.82% | 5 |
|
|
2014
Q1 | $1.94B | Sell |
6,337,153
-168,678
| -3% | -$53.5M | 1.85% | 5 |
|
|
2013
Q4 | $1.82B | Buy |
6,505,831
+117,882
| +2% | +$30.5M | 1.79% | 5 |
|
|
2013
Q3 | $1.54B | Sell |
6,387,949
-72
| -0% | -$16.1K | 1.61% | 6 |
|
|
2013
Q2 | $1.37B | Buy |
+6,388,021
| New | +$1.37B | 1.55% | 7 |
|
Other funds holding BIIB
Jennison Associates's BIIB Position: Q2 2023 in Review
Jennison Associates sold out of Biogen (BIIB) in Q2 2023, closing a stake of 61,787 shares — an estimated $17.2M sold.
Jennison Associates first reported a position in BIIB in Q2 2013 and held it in 27 quarters. The position peaked at $2.15B in Q1 2015. 1,008 funds tracked by Wall St. Rank hold BIIB as of Q2 2023.
- Jennison Associates reported no remaining Biogen position as of Q2 2023 after selling out during the quarter.
- Jennison Associates sold 61,787 Biogen shares in Q2 2023, an estimated $17.2M.
- Jennison Associates first reported a position in Biogen in Q2 2013 and held it in 27 quarters.
- Jennison Associates's Biogen position peaked at $2.15B in Q1 2015.
- 1,008 funds tracked by Wall St. Rank held Biogen as of Q2 2023.
Based on Jennison Associates's 13F filing for Q2 2023, filed 3 Aug 2023.